Polystyrene Sulfonate (Solystat, Kayexalate) shortage status
Widespread shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Also sold as: Solystat, Kayexalate, K-Exit Poudre
Polystyrene Sulfonate is in a widespread shortage in Canada. 3 of 6 reported products are affected. The latest manufacturer estimate for full recovery is Oct 9, 2026.
A potassium binder used to treat high potassium levels in the blood.
Products affected
3 / 6
In shortage since
Nov 1, 2024
Est. full return
Oct 9, 2026
Reports on file
27
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · since Dec 22, 2025, est. end Aug 17, 2026 · Shortage of an active ingredient.
Active shortage
JAMP SODIUM POLYSTYRENE SULFONATE
1G · POWDER FOR SUSPENSION · JAMP PHARMA CORPORATION
DIN 02497557 · since Apr 21, 2026, est. end Oct 9, 2026 · Disruption of the manufacture of the drug.
Active shortage
ODAN-SODIUM POLYSTYRENE SULFONATE
250MG · SUSPENSION · ODAN LABORATORIES LTD
DIN 02473968 · since Nov 1, 2024, no end estimate · Disruption of the manufacture of the drug.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Aug 8, 2025 · Shortage of an active ingredient.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended May 8, 2025 · Shortage of an active ingredient.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Mar 31, 2025 · Shortage of an active ingredient.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Feb 21, 2025 · Disruption of the manufacture of the drug.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Jan 17, 2025 · Disruption of the manufacture of the drug.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Nov 8, 2024 · Disruption of the manufacture of the drug.
Resolved
SOLYSTAT
1G · POWDER FOR SUSPENSION
POWDER · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00755338 · ended Oct 15, 2024 · Shortage of an active ingredient.
Resolved
SOLYSTAT
250MG · SUSPENSION · PENDOPHARM DIVISION OF PHARMASCIENCE INC
DIN 00769541 · ended Aug 30, 2024 · Shortage of an active ingredient.
Resolved
KAYEXALATE
1G · POWDER FOR SUSPENSION
POWDER · SANOFI-AVENTIS CANADA INC
DIN 02026961 · ended Jul 31, 2024
Showing 12 of 27 reports. All reports are on file with Health Canada.
What's happening
Polystyrene Sulfonate is currently affected by 3 active shortage reports filed with Health Canada by PENDOPHARM DIVISION OF PHARMASCIENCE INC, JAMP PHARMA CORPORATION, ODAN LABORATORIES LTD.
The reported causes are: shortage of an active ingredient; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Polystyrene Sulfonate is classified under “ALL OTHER THERAPEUTIC PRODUCTS” (ATC V03AE).
Recent changes
No changes recorded yet.
Common questions
What is Polystyrene Sulfonate used for?
A potassium binder used to treat high potassium levels in the blood.
When will Polystyrene Sulfonate be back in stock in Canada?
The latest manufacturer estimate is Oct 9, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Polystyrene Sulfonate in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.